Quick Takeaways
- Vestal Point Capital, LP filed SCHEDULE 13G for TENAX THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (TENX).
- Disclosed ownership: 9.9%.
- Date of event: 30 Sep 2024.
Vestal Point Capital, LP - 30 Sep 2024 SCHEDULE 13G Report for TENAX THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (TENX)
- Filing Manager
- Vestal Point Capital, LP
- Reporting Manager
- Vestal Point Capital, LP
- Symbol
- TENX
- Shares outstanding
- 24,950,465 shares
- Disclosed Ownership
- 2,470,096 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Nov 2025, 16:07:29 UTC
- Date of event
- 30 Sep 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Vestal Point Capital, LP disclosed 9.9% ownership in TENAX THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (TENX) on 30 Sep 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 16:07.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vestal Point Capital, LP | 9.9% | 2,470,096 | 0 | 2,470,096 | /s/ Ryan Wilder | By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner | |
| Ryan Wilder | 9.9% | 2,470,096 | 0 | 2,470,096 | /s/ Ryan Wilder | Ryan Wilder, Individually |